论文信息 - A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). - 字舞流文

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).

J. Sehouli | F. Cognetti | N. Colombo | G. Scambia | P. Harter | F. Nathan | P. Wimberger | A. Savarese | K. Baumann | A. Bagnato | R. Sorio | E. Mari | S. Mcintosh | K. Pemberton | S. McIntosh